報價延遲最少15分鐘:2025/01/11 17:18 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.80/-0.24
|
|
企業價值
2.66B
|
| 資產負債 |
|
每股賬面淨值
6.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
266.72M
|
|
每股收益
2.42
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:18 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. |